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Summary
Objective:  The  objective  of  this  study  was  to  evaluate  the  prognostic  impact  of  tumour  multi-
focality in  papillary  thyroid  microcarcinoma  (PTMC).
Methods:  All  patients  who  underwent  total  thyroidectomy  and  central  neck  dissection  for  PTMC
in our  institution  between  1990  and  2007  were  included  in  this  retrospective  study.  Statisti-
cal correlations  between  tumour  multifocality  and  various  clinical  or  pathological  prognostic
parameters  were  assessed  by  univariate  and  multivariate  analyses.
Results:  A  total  of  160  patients  (133  women  and  27  men;  mean  age:  47.8  ±  13.7  years)  were
included  in  this  study.  Tumour  multifocality  was  demonstrated  in  59  (37%)  patients.  Central  neck
metastatic lymph  node  involvement  was  identiﬁed  in  46  (28%)  patients.  No  statistical  correla-
tion was  demonstrated  between  tumour  multifocality  and  the  following  factors:  age,  gender,
tumour size,  extension  beyond  the  thyroid,  metastatic  central  neck  lymph  node  involvement
mouand risk  of  recurrence.  A  tu
of recurrence  (P  =  0.008).
Conclusion:  Tumour  multifocalit
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doi:10.1016/j.anorl.2011.11.003r  diameter  greater  than  5  mm  was  associated  with  a  higher  risky  does  not  appear  to  have  a  prognostic  impact  in  PTMC.
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Table  1  Patient  characteristics.
Characteristics  n  =  160  Percentage  (%)
Gender
Female  133  83
Male 27  17
Age
> 45  years  90  56
< 45  years  70  44
Comorbidity
ASA I 86 54
ASA  II 66 41
ASA  III 8 5
Surgical  indicationa
Multinodular  goitre  65  41
Hyperthyroidism  11  7
Suspicious  micronodule  61  38
Other suspicious  nodule  23  14
Adjuvant  Iodine-131  therapy  129  81
a Indication for thyroid surgery: suspicious micronodule: nod-
ule corresponding to papillary microcarcinoma; other suspicious
nodule: surgery justiﬁed by the suspicious nature of a nodule
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ntroduction
apillary  carcinoma  is  the  most  common  histological  type
f  malignant  thyroid  tumour.  These  lesions  are  increasingly
iagnosed  at  the  stage  of  microcarcinoma,  i.e.  lesions  no
arger  than  10  mm  in  diameter  [1—3]. The  prognosis  of  papill-
ry  thyroid  microcarcinoma  (PTMC)  is  generally  excellent
nd  treatment  of  these  tumours  is  increasingly  well  deﬁned
4,5],  as  several  French,  European  and  American  consen-
us  conferences  have  established  guidelines  for  diagnosis
nd  treatment  [6—8]. Nevertheless,  many  aspects  remain
oorly  elucidated,  especially  concerning  the  indications  for
rophylactic  central  neck  dissection  (level  VI)  or  Iodine-131
emnant  ablation.  Although  some  factors  have  been  clearly
dentiﬁed  as  having  a  negative  prognostic  impact,  the  role
f  certain  clinical  and  laboratory  parameters  remains  more
ontroversial.  For  example,  tumour  multifocality  raises  the
uestion  of  the  need  for  Iodine-131  remnant  ablation,  but
oes  not  constitute  a  formal  indication  for  this  adjuvant
herapy  [6].  Tumour  multifocality  is  a  frequent  event  and
aises  many  management  problems  in  everyday  practice.
The  objective  of  this  study  was  therefore  to  investi-
ate  clinical  and  histological  factors  associated  with  tumour
ultifocality  and  the  prognostic  impact  of  these  factors  in
TMC.
aterial and methods
 retrospective  study  was  conducted  on  all  patients  who
nderwent  total  thyroidectomy  and  central  neck  dissection
or  PTMC  between  1990  and  2007  in  our  institution.
During  this  period,  770  patients  were  operated  for  papil-
ary  thyroid  carcinoma  in  our  institution,  including  414  cases
54%)  of  PTMC.  One  hundred  and  sixty  of  these  patients
ere  treated  surgically  comprising  total  thyroidectomy  and
entral  neck  dissection  and  were  therefore  included  in  this
tudy.
The  following  parameters  were  collected  from  review  of
he  patients’  computerized  medical  records:
patient  characteristics:  age,  gender,  comorbidities  (ASA
score);
histological  data:  tumour  size,  tumour  multifocality  and
bilateral  involvement,  extension  beyond  the  thyroid,
presence  of  metastatic  central  neck  lymph  node  involve-
ment;
 iodine-131  remnant  ablation;
 cancer  events:  local  recurrence,  metastatic  cervical
lymph  nodes  or  distant  metastases;
 patient’s  status  at  the  time  of  the  study  (June  2011)  or  at
the  date  of  last  news:  alive  (in  remission  or  recurrence)
or  deceased  (from  PTMC  or  other  cause).
Overall  survival  of  the  patients  was  determined  by  the
aplan-Meier  method.
Univariate  and  multivariate  analyses  were  performed  to
dentify  statistical  correlations  between  tumour  multifo-
ality  and  the  following  clinical  and  histological  factors:
he  patient’s  age  and  gender,  tumour  size  and  exten-
ion  beyond  the  thyroid.  Factors  predictive  of  central
eck  metastatic  lymph  node  involvement  (level  VI)  at
A
1
r
Tother than papillary microcarcinoma.
iagnosis  were  assessed  by  univariate  and  multivariate  anal-
ses  comprising  the  following  factors:  the  patient’s  age  and
ender,  tumour  size,  extension  beyond  the  thyroid,  tumour
ultifocality,  and  bilateral  involvement  and  predictive  fac-
ors  of  tumour  recurrence  were  assessed  by  univariate  and
ultivariate  analyses  comprising  the  following  factors:  the
atient’s  age  and  gender,  tumour  size,  extension  beyond  the
hyroid,  tumour  multifocality,  bilateral  involvement,  central
eck  metastatic  lymph  node  involvement  at  diagnosis  and
djuvant  Iodine-131  therapy.
A  Chi-square  test  conﬁrmed  by  Fisher’s  exact  test
qualitative  variables)  was  used  for  univariate  analyses  and
ogistic  regression  models  were  used  for  multivariate  analy-
es.  All  variables  with  a  P  value  <  0.10  on  univariate  analysis
ere  entered  into  multivariate  analysis.  All  statistical  tests
ere  performed  with  R.2.10.1  software  for  Windows  with  a
imit  of  signiﬁcance  of  5%  on  two-tailed  tests.
esults
atient  characteristics
 total  of  160  patients  were  included  in  this  study:  133
omen  and  27  men  with  a  mean  age  of  47.8  ±  13.7  years
range:  18  to  79  years).  All  patients  included  in  this
tudy  underwent  total  thyroidectomy  with  central  neck
issection.  PTMC  was  identiﬁed  on  preoperative  exami-
ations  (ultrasound  ±  aspiration  cytology)  as  a suspicious
icronodule  in  61  cases.  PTMC  was  therefore  consid-
red  to  be  an  incidental  ﬁnding  in  the  other  99  cases.
fter  surgery,  129  patients  (81%)  received  adjuvant  Iodine-
31  therapy.  No  patient  required  external  beam  radiothe-
apy  or  chemotherapy.  Patient  characteristics  are  shown  in
able  1.
Prognostic  impact  of  tumour  multifocality  in  thyroid  papillary  m
Table  2  Histological  characteristics.
Characteristics n  =  160  Percentage  (%)
Tumour  multifocality  59  37
Bilateral  tumour  32  20
Size
≤ 5  mm  62  39
> 5  mm  98  61
Extension  beyond  the  thyroid 8 5
Lymph  node  involvementa
Ipsilateral  involvement 37 23
Contralateral  involvement 2 1
Bilateral  involvement  7  4
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ca A total of 46 patients presented central neck lymph node
involvement.
Histological  data
In  this  series  of  160  patients  with  PTMC,  59  presented
multifocal  lesions  and  32  presented  bilateral  lesions.  Mean
tumour  diameter  (largest  lesion  in  the  case  of  multifo-
cal  tumours)  was  6.8  ±  2.6  mm.  Central  neck  lymph  node
involvement  was  present  in  46  patients  (28%),  22  of  whom
presented  multiple  lymph  nodes  involvement  (at  least  two
metastatic  nodes).  The  mean  number  of  central  neck
lymph  nodes  removed  was  9.0  ±  5.1.  The  mean  number  of
metastatic  central  neck  lymph  nodes  in  patients  with  lymph
node  involvement  was  2.3  ±  1.5.  Histological  characteristics
are  shown  in  Table  2.
Patient  follow-up  and  cancer  outcome
At  the  time  of  this  study,  four  patients  had  died,  all  from
causes  other  than  PTMC.  The  5-year  overall  survival  was
94.8%.  Ten  cases  of  recurrence  were  detected,  including
one  local  recurrence  in  the  thyroidectomy  site  (treated  by
surgery  and  Iodine-131  therapy),  ﬁve  lateral  neck  regional
recurrences  (four  treated  by  neck  dissection  and  Iodine-131
therapy  and  one  treated  exclusively  by  Iodine-131  therapy),
one  lung  metastasis  (treated  by  Iodine-131  therapy)  and
r
o
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Table  3  Predictive  factors  of  lymph  node  involvement  and  tumou
Parameters  Central  neck  lym
P  (UA)/(MA)
Age
(<  45  years)
0.003/0.009
OR  =  2.7  [1.3—5.
Gender
(male)
0.002/0.002
OR  =  4.1  [1.6—10
Tumour  size
(>  5  mm)
0.009/0.02
OR  =  2.7  [1.2—6.
Tumour  multifocality  0.59/—  
Extension beyond  the  thyroid  0.69/—  
Lymph node  involvement  —  
Iodine-131 therapy  —  
P (UA): P value on univariate analysis (Chi-square test conﬁrmed by Fish
regression). OR: odds ratio; OR values are indicated together with thei
a Multivariate analysis not performed as only one factor was signiﬁcaicrocarcinoma  177
hree  cases  of  isolated  biochemical  recurrence  (elevation
f  thyroglobulin  with  no  recurrence  formally  identiﬁed  on
maging  examinations,  treated  by  Iodine-131  therapy).  No
atient  included  in  this  study  presented  active  cancer  at
he  end  of  follow-up.
actors  associated  with  tumour  multifocality  and
rognostic  impact
nivariate  and  multivariate  analyses  failed  to  demonstrate
ny  statistically  signiﬁcant  correlation  between  tumour  mul-
ifocality  and  the  following  factors:  age,  gender,  tumour
ize,  extension  beyond  the  thyroid,  central  neck  lymph  node
nvolvement  at  diagnosis  and  risk  of  recurrence.  Similarly,
o  statistically  signiﬁcant  correlation  was  observed  between
ilateral  tumours  and  these  same  factors.
In  contrast,  age  (<  to  45  years;  P  =  0.003),  male  gen-
er  (P  =  0.002)  and  tumour  size  (>5  mm;  P =  0.009)  were
ssociated  with  a  higher  risk  of  central  neck  lymph  node
nvolvement  at  diagnosis  on  univariate  analysis.  Lymph  node
nvolvement  was  detected  on  central  neck  dissection  in  16%
f  patients  when  tumour  size  (T)  was  ≤  5  mm  versus  37%
hen  T  was  >  5  mm.  These  results  were  conﬁrmed  on  mul-
ivariate  analysis  (age:  P  =  0.009;  male  gender:  P  = 0.002;
umour  size:  P  =  0.02).
Among  the  various  parameters  studied,  tumour  size
>5  mm;  P  =  0.008)  was  the  only  factor  associated  with  a  sig-
iﬁcantly  higher  risk  of  tumour  recurrence.  These  analyses
re  shown  in  Table  3.
iscussion
he  incidence  of  PTMC  is  on  the  increase  in  industrialized
ountries  due  to  earlier  diagnosis  of  thyroid  cancers  and
ossibly  also  an  increase  in  the  real  incidence  of  this  dis-
ase  [1—3]. According  to  many  authors,  PTMC  is  the  most
ommon  histological  type  of  thyroid  cancers  [2—9].The  diagnostic  and  therapeutic  management  of  diffe-
entiated  thyroid  cancer  has  been  regularly  the  subject
f  French,  European  and  American  consensus  conferences
6—8]  and  is  therefore  increasingly  well-deﬁned.  However,  a
r  recurrence.
ph  node  involvement Risk  of  recurrence
P (UA)/(MA)
8]
0.18/—
.4]
0.65/—
4]
0.008/a
0.16/—
0.37/—
0.12/—
0.98/—
er’s exact test); P (MA): P value on multivariate analysis (logistic
r 95% conﬁdence intervals.
nt on univariate analysis.
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[78  
umber  of  questions  remain  unresolved,  leading  to  a  certain
egree  of  variability  in  the  management  of  patients  from
ne  centre  to  another  and  according  to  the  various  schools  of
hought.  One  of  these  incompletely  resolved  issues  concerns
he  indications  for  central  neck  dissection  in  the  absence
f  identiﬁed  lymph  node  metastasis  (prophylactic  dissec-
ion)  and  Iodine-131  therapy  [6—10]. For  example,  according
o  French  guidelines  for  the  management  of  patients  with
ifferentiated  follicular  thyroid  cancer,  there  is  no  consen-
us  concerning  the  need  for  adjuvant  Iodine-131  therapy
fter  surgery  in  patients  with  N0  or  Nx  multifocal  PTMC
6].  Tumour  multifocality  is  a  particularly  frequent  event
n  PTMC  (37%  PTMC  in  the  present  series)  and  is  therefore
he  subject  of  numerous  discussions  at  thyroid  cancer  mul-
idisciplinary  consensus  conferences.
We  therefore  decided  to  investigate  the  prognos-
ic  impact  of  tumour  multifocality  in  PTMC,  as  tumour
ultifocality  raises  fewer  treatment-related  problems  in
acrocarcinoma,  which  generally  requires  adjuvant  Iodine-
31  therapy.  This  study  was  based  on  a  patient  population
ndergoing  relatively  homogeneous  surgical  management
total  thyroidectomy  and  central  neck  dissection)  to
liminate  the  inﬂuence  of  extent  of  initial  surgery  on  the
isk  of  recurrence.  Inclusion  of  only  patients  who  had  under-
one  central  neck  dissection  also  provided  us  with  lymph
ode  staging  (N  stage),  which  is  an  important  prognostic
actor.  Furthermore,  in  view  of  the  excellent  prognosis  of
TMC,  we  studied  the  prognostic  impact  of  various  fac-
ors  on  risk  of  recurrence  rather  than  survival  or  on  other
arameters  known  to  have  a  prognostic  impact  (exten-
ion  beyond  the  thyroid,  cervical  lymph  node  involvement,
tc.).
This  series  demonstrated  the  frequency  of  tumour
ultifocality  and  the  absence  of  correlation  between  mul-
ifocality  and  various  factors  such  as  age,  gender,  tumour
ize  and  extension  beyond  the  thyroid.  Furthermore,  in  this
tudy,  multifocal  tumours  were  not  associated  with  a  higher
isk  of  central  neck  lymph  node  involvement  or  tumour
ecurrence.
The  fairly  classical  correlation  between  central  neck
ymph  node  involvement  and  age  <  45  years,  male  gender
nd  tumour  size  was  also  demonstrated.  The  risk  of  tumour
ecurrence  was  also  shown  to  be  correlated  with  tumour
ize.  It  should  also  be  noted  that  although  young  age  is  clas-
ically  associated  with  a  higher  incidence  of  cervical  lymph
ode  involvement,  it  is  nevertheless  a  recognized  factor  of
ood  prognosis  in  thyroid  cancer  [6,7,10].  Tumour  size  also
lays  a  role  in  local  and  regional  disease  progression,  even  in
icrocarcinoma,  as  several  authors  have  reported  a  higher
isk  of  lymph  node  involvement  for  lesions  larger  than  5  mm
4,9,11,12].
The  majority  of  patients  with  unifocal  or  multifocal
TMC  in  this  series  were  treated  by  adjuvant  Iodine-131
herapy,  as  this  study  included  patients  operated  between
990  and  2007.  Many  of  these  patients  were  therefore
reated  according  to  older  guidelines.  Recent  guidelines
oncerning  the  management  of  thyroid  cancer  have  led  us
o  considerably  reduce  the  indications  for  adjuvant  Iodine-
31  therapy.  Iodine-131  therapy  can  constitute  a  bias  in  this
[J.-C.  Riss  et  al.
tudy,  as  it  can  decrease  the  risk  of  recurrence  in  patients
ith  multifocal  PTMC.  However,  this  factor  (presence  or
bsence  of  Iodine-131  therapy)  was  taken  into  account  in
tatistical  analyses  of  the  risk  of  recurrence.
The  results  of  this  retrospective  series  support  the
pinion  of  the  American  Thyroid  Association  (ATA),  which
oes  not  recommend  Iodine-131  remnant  ablation  for  multi-
ocal  PTMC  in  the  absence  of  other  factors  of  poor  prognosis
8].  An  alternative  approach  currently  under  evaluation
ould  be  to  propose  low-dose  Iodine-131  therapy  (30  mCi).
onclusion
umour  multifocality  is  a  frequent  event  in  PTMC  but  does
ot  appear  to  have  a  negative  prognostic  impact.
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